CN114728973A - 一种核蛋白抑制剂的晶型及其应用 - Google Patents

一种核蛋白抑制剂的晶型及其应用 Download PDF

Info

Publication number
CN114728973A
CN114728973A CN202080078475.6A CN202080078475A CN114728973A CN 114728973 A CN114728973 A CN 114728973A CN 202080078475 A CN202080078475 A CN 202080078475A CN 114728973 A CN114728973 A CN 114728973A
Authority
CN
China
Prior art keywords
degrees
angles
following
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078475.6A
Other languages
English (en)
Inventor
贺海鹰
夏建华
谭海忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN114728973A publication Critical patent/CN114728973A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

涉及式(I)化合物、其水合物、其溶剂合物、或者水与溶剂共合物的晶型，以及其在制备治疗与HBV相关疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (29)

  1. PCT国内申请，权利要求书已公开。
CN202080078475.6A 2019-11-22 2020-11-20 一种核蛋白抑制剂的晶型及其应用 Pending CN114728973A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019111719783 2019-11-22
CN201911171978 2019-11-22
PCT/CN2020/130612 WO2021098850A1 (zh) 2019-11-22 2020-11-20 一种核蛋白抑制剂的晶型及其应用

Publications (1)

Publication Number Publication Date
CN114728973A true CN114728973A (zh) 2022-07-08

Family

ID=75980397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078475.6A Pending CN114728973A (zh) 2019-11-22 2020-11-20 一种核蛋白抑制剂的晶型及其应用

Country Status (7)

Country Link
US (1) US20230026869A1 (zh)
EP (1) EP4063366A4 (zh)
JP (1) JP2023502675A (zh)
CN (1) CN114728973A (zh)
AU (1) AU2020385518A1 (zh)
CA (1) CA3159096A1 (zh)
WO (1) WO2021098850A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
SG11202012346YA (en) 2018-06-11 2021-01-28 Venatorx Pharmaceuticals Inc Hepatitis b capsid assembly modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790168A (zh) * 2016-08-26 2019-05-21 吉利德科学公司 取代的吡咯嗪化合物及其用途
WO2019165374A1 (en) * 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019223791A1 (zh) * 2018-05-25 2019-11-28 正大天晴药业集团股份有限公司 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101328171A (zh) 2007-06-18 2008-12-24 张中能 一种溴苯基-取代的噻唑二氢嘧啶
TWI730985B (zh) * 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
JP6904970B2 (ja) * 2016-03-07 2021-07-21 エナンタ ファーマシューティカルズ インコーポレイテッド Ｂ型肝炎抗ウイルス剤
CN107778310A (zh) * 2016-08-31 2018-03-09 上海市第人民医院 乙肝病毒靶向人La蛋白的抑制剂HBSC11及其衍生物和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790168A (zh) * 2016-08-26 2019-05-21 吉利德科学公司 取代的吡咯嗪化合物及其用途
WO2019165374A1 (en) * 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019223791A1 (zh) * 2018-05-25 2019-11-28 正大天晴药业集团股份有限公司 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Also Published As

Publication number Publication date
AU2020385518A1 (en) 2022-06-09
JP2023502675A (ja) 2023-01-25
EP4063366A4 (en) 2023-12-20
EP4063366A1 (en) 2022-09-28
WO2021098850A1 (zh) 2021-05-27
US20230026869A1 (en) 2023-01-26
CA3159096A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP6676602B2 (ja) 上皮成長因子受容体キナーゼ阻害剤の塩
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
US10626118B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
TWI762743B (zh) 磺醯胺化合物及其用途
CN111763215B (zh) 一种具有含氮杂环结构的化合物及其制备方法和用途
EP3679029A1 (en) Imidazolidine compounds
US20220363634A1 (en) Crystalline form of capsid protein assembly inhibitor containing n hetero five-membered ring, and application thereof
CN114728973A (zh) 一种核蛋白抑制剂的晶型及其应用
WO2021143843A1 (zh) 一种pde3/pde4双重抑制剂的结晶及其应用
JP2022504765A (ja) ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
CN108676009B (zh) 作为her2酪氨酸激酶抑制剂的嘧啶衍生物及其应用
WO2020063856A1 (zh) 作为flt3和axl抑制剂的3,9-二氮杂螺[5,5]十一烷类化合物
US11230559B2 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate
US20220332684A1 (en) Crystal form of five-membered n heterocyclic compound, and application thereof
WO2018041260A1 (zh) 一类溴结构域识别蛋白抑制剂及其制备方法和用途
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
WO2017157137A1 (zh) 一种新型的无环核苷类似物及其药物组合物
CN110092799B (zh) 一种环状化合物、其制备方法和应用
US20220119415A1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CA3221997A1 (en) Compound as cdk kinase inhibitor and use thereof
CN111057069A (zh) 一种环状化合物、其应用及组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination